Close Menu

NEW YORK – Myriad Genetics said Monday that it has submitted a supplementary application to the Japanese Ministry of Health Labor and Welfare for use of its BRACAnalysis Diagnostic System as a companion diagnostic to identify patients with metastatic pancreatic or metastatic castration-resistant prostate cancer who have germline BRCA1 and BRCA2 mutations and may be candidates for targeted therapy with the PARP inhibitor olaparib (AstraZeneca's Lynparza), subject to regulatory approval.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.